G1 Therapeutics Inc
NASDAQ:GTHX
G1 Therapeutics Inc
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 148 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The firm's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 148 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The firm's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
